# What Is Tirzepatide? The Dual GIP/GLP-1 Peptide Explained > What is tirzepatide? A 39-amino-acid FDA-approved dual GIP and GLP-1 receptor agonist. Mechanism, approvals, and the islet-function evidence explained. ## TL;DR What is tirzepatide? Short answer: a once-weekly prescription injection that lowers blood sugar and body weight by working on two hormone receptors that most similar drugs only hit one of. It is FDA-approved — that matters because it means large, independent phase 3 trials tested it in tens of thousands of real patients, not just lab mice. The compound works by mimicking two gut hormones — GIP and GLP-1 — that normally tell the pancreas to release insulin after a meal. By activating both receptors at once, tirzepatide produces more insulin when needed, suppresses glucagon (the hormone that raises blood sugar), slows how fast the stomach empties, and reduces appetite. The result is measurably better blood-sugar control and more weight loss than drugs targeting just one of those two hormones. For most of what people actually want to know — what it feels like, the side effects, who should be careful — the [Tirzepatide effects](/effects) page is the place to start. ## What is tirzepatide? What is tirzepatide? It is a synthetic 39-amino-acid peptide designed to activate both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R) with a single molecule [1]. In pharmacological terms it is a dual incretin (gut-hormone) agonist — sometimes called a 'twincretin' or dual incretin mimetic. The molecule was developed under the code name LY3298176 and first reported in 2018, when it was shown to activate both receptor pathways in vitro and produce greater reductions in body weight and food intake in mice than a selective GLP-1 receptor agonist [1]. The FDA approved it for type 2 diabetes in May 2022 and for obesity in November 2023 [12]. The chemical identity: molecular formula C225H348N48O68, molecular weight 4,813.53 Da, CAS 2023788-19-2. The peptide backbone is built on the native GIP sequence and carries a C20 fatty diacid (eicosanedioic acid) modification that enables high albumin binding, extending the elimination half-life to approximately five days [1] — long enough to support once-weekly dosing. ## GIP and GLP-1: what the two receptors do GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) are both incretins — gut hormones released after eating that signal the pancreas to secrete insulin when blood glucose is elevated. They work in a glucose-dependent manner, meaning they amplify insulin release when glucose is high but not when it is normal, which constrains hypoglycaemia risk during monotherapy [1]. GLP-1 receptor agonism: stimulates insulin secretion, suppresses glucagon (the counter-regulatory hormone that raises blood glucose), slows gastric emptying, and acts centrally to reduce appetite and food intake. Selective GLP-1 receptor agonists have been clinically available since 2005. GIP receptor agonism: also stimulates glucose-dependent insulin secretion and has distinct downstream effects on adipose-tissue metabolism, fat storage, and potentially central appetite regulation — effects that appear partly complementary to and partly distinct from GLP-1 receptor signalling [1]. In receptor-signalling assays, tirzepatide engages the GIP receptor more fully than the GLP-1 receptor (an 'imbalanced' dual agonist) and shows biased GLP-1R signalling favouring cAMP generation over beta-arrestin recruitment [2]. The proposed significance: biased agonism at the GLP-1R may prolong the insulinotropic signal without the rapid receptor internalisation that attenuates the response to native GLP-1, potentially contributing to the larger glycaemic effects seen in trials [2]. ## What tirzepatide is used for (approved indications) Tirzepatide is used for three FDA-approved indications [12]: 1. **Type 2 diabetes mellitus** — to improve glycaemic control as an adjunct to diet and exercise (approved May 2022). 2. **Chronic weight management** — in adults with initial BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related condition (approved November 2023). 3. **Obstructive sleep apnea** — moderate-to-severe OSA in adults with obesity (subsequently approved). Use in type 1 diabetes is not approved. The compound is not indicated for treatment of type 2 diabetes in paediatric patients on this label. The SURPASS-2 phase 3 trial (n=1,879, 40 weeks) documented HbA1c reductions of 2.01/2.24/2.30 percentage points at 5/10/15 mg versus 1.86 percentage points with the active comparator, establishing glycaemic superiority at all three doses [3]. The SURMOUNT-1 phase 3 trial (n=2,539, 72 weeks) documented mean weight reductions of -15.0/-19.5/-20.9% at the three doses versus -3.1% with placebo [4]. For the read on [what is tirzepatide](/what-is-tirzepatide) at the islet level, the mechanistic story is on the [tirzepatide mechanism of action](/mechanism-of-action) page. ## Tirzepatide peptide vs GLP-1 agonists Tirzepatide peptide differs from selective GLP-1 receptor agonists in one fundamental respect: it adds full GIP receptor engagement to the GLP-1 receptor signal. The clinical consequence was measured directly in SURMOUNT-5 (n=751, 72 weeks) — a head-to-head open-label trial comparing tirzepatide maximum tolerated dose (10 or 15 mg) versus the maximum tolerated dose of a leading GLP-1 receptor agonist (1.7 or 2.4 mg). Tirzepatide produced -20.2% body-weight reduction versus -13.7% (P<0.001); tirzepatide participants also reached ≥10%, ≥15%, ≥20%, and ≥25% weight-loss thresholds at higher rates [5]. In a network meta-analysis of 38 phase 3/4 placebo-controlled RCTs (16,660 T2DM participants, 104 study arms), tirzepatide 15 mg produced the largest HbA1c reduction (-1.79%) of all incretin-class agents studied, while gastrointestinal adverse-event odds ratios were similar across agents regardless of efficacy magnitude [11]. For the beta-cell and insulin-sensitivity comparison, Heise et al. (2022) showed tirzepatide produced a clamp disposition index ETD of 0.84 versus the comparator (95% CI 0.46-1.21) and a M-value improvement ETD of 1.52 mg/min/kg [8]. The Mather 2024 exploratory analysis found the insulin-sensitivity benefit per unit of weight loss was greater with tirzepatide (slope of M-value change vs weight change differed, P=0.0461), suggesting a dual-incretin mechanism contributes to insulin sensitisation beyond weight reduction alone [9]. --- Trial figures read from primary sources. Not a clinic, not a dispenser, not a recommendation.